Full Study Report of Andexanet Alfa for Bleeding Associated with Factor Xa Inhibitors
Stuart J. Connolly(Population Health Research Institute), Truman J. Milling(Population Health Research Institute), C. Michael Gibson(Brigham and Women's Hospital), Brandi Meeks(Population Health Research Institute), Genmin Lu(Portola Pharmaceuticals (United States)), Elena Zotova(Population Health Research Institute), Andrew M. Demchuk(Los Angeles Medical Center), Daniel J. Pallin(Brigham and Women's Hospital), Sônia Francisca de Souza(Population Health Research Institute), Shelly Goodman(Population Health Research Institute), Jeannot Schmidt(Population Health Research Institute), Mauricio Concha(Population Health Research Institute), Pamela B. Conley(Portola Pharmaceuticals (United States)), Peter Verhamme(KU Leuven), John H. Lawrence(Population Health Research Institute), Juliet Nakamya(Population Health Research Institute), Mark Crowther(McMaster University), Deborah Siegal(Population Health Research Institute), Janet M. Leeds(Portola Pharmaceuticals (United States)), Michele Bronson(Portola Pharmaceuticals (United States)), John W. Eikelboom(King's College Hospital), José López‐Sendón(Hospital Universitario La Paz), Sadia Ahmad(Population Health Research Institute), Jan Beyer‐Westendorf(Population Health Research Institute), Pierre Albaladejo(Population Health Research Institute), John T. Curnutte(Portola Pharmaceuticals (United States)), Saskia Middeldorp(Amsterdam UMC Location University of Amsterdam), Patrick Yue(Population Health Research Institute), Alexander T. Cohen(St Thomas' Hospital)
Cited by 945
Related Papers
Dabigatran versus Warfarin in Patients with Atrial Fibrillation
|New England Journal of Medicine|2009|11.2k
Endovascular thrombectomy after large-vessel ischaemic stroke: a meta-analysis of individual patient data from five randomised trials
|The Lancet|2016|7.6k
Prasugrel versus Clopidogrel in Patients with Acute Coronary Syndromes
|New England Journal of Medicine|2007|6.7k
COVID-19 and Thrombotic or Thromboembolic Disease: Implications for Prevention, Antithrombotic Therapy, and Follow-Up
|Journal of the American College of Cardiology|2020|2.9k
Rivaroxaban with or without Aspirin in Stable Cardiovascular Disease
|New England Journal of Medicine|2017|2.4k